Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

northwind pharmaceuticals, llc - pravastatin sodium (unii: 3m8608uq61) (pravastatin - unii:kxo2kt9n0g) - pravastatin sodium 40 mg - pravastatin sodium tablets are indicated: - to reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (ldl-c) without clinically evident coronary heart disease (chd). - to reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident chd. - as an adjunct to diet to reduce ldl-c in adults with primary hyperlipidemia. - as an adjunct to diet to reduce ldl-c in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (hefh). - as an adjunct to diet for the treatment of adults with: primary dysbetalipoproteinemia. hypertriglyceridemia. - primary dysbetalipoproteinemia. - hypertriglyceridemia. - acute liver failure or decompensated cirrhosis [see warning

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - pravastatin sodium (unii: 3m8608uq61) (pravastatin - unii:kxo2kt9n0g) - pravastatin sodium 20 mg - pravastatin sodium tablet is indicated: - to reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (ldl-c) without clinically evident coronary heart disease (chd). - to reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident chd. - as an adjunct to diet to reduce ldl-c in adults with primary hyperlipidemia. - as an adjunct to diet to reduce ldl-c in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (hefh). - as an adjunct to diet for the treatment of adults with: primary dysbetalipoproteinemia hypertriglyceridemia - primary dysbetalipoproteinemia - hypertriglyceridemia - acute liver failure or decompensated cirrhosis

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - pravastatin sodium (unii: 3m8608uq61) (pravastatin - unii:kxo2kt9n0g) - pravastatin sodium 10 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in hypercholesterolemic patients without clinically evident coronary heart disease (chd), pravastatin sodium tablets are indicated to: - reduce the risk of myocardial infarction (mi). - reduce the risk of undergoing myocardial revascularization procedures. - reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. in patients with clinically evident chd, pravastatin sodium tablets are indicated to: - reduce the risk of total mortality by reducing coronary death. - reduce the risk of mi. - reduce the risk of undergoing myocardial revascularization procedures. - reduce the risk

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - pravastatin sodium (unii: 3m8608uq61) (pravastatin - unii:kxo2kt9n0g) - pravastatin sodium 10 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in hypercholesterolemic patients without clinically evident coronary heart disease (chd), pravastatin sodium tablet, usp is indicated to: -   reduce the risk of myocardial infarction (mi). -   reduce the risk of undergoing myocardial revascularization procedures. -   reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. in patients with clinically evident chd, pravastatin sodium tablet is indicated to: -   reduce the risk of total mortality by reducing coronary death. -   reduce the risk of mi. -   reduce the risk of undergoing myocardial revascularization procedures. -  

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

remedyrepack inc. - pravastatin sodium (unii: 3m8608uq61) (pravastatin - unii:kxo2kt9n0g) - pravastatin sodium 80 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in hypercholesterolemic patients without clinically evident coronary heart disease (chd), pravastatin sodium tablets are indicated to: - reduce the risk of myocardial infarction (mi). - reduce the risk of undergoing myocardial revascularization procedures. - reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. in patients with clinically evident chd, pravastatin sodium tablets are indicated to: - reduce the risk of total mortality by reducing coronary death. - reduce the risk of mi. - reduce the risk of undergoing myocardial revascularization procedures. - reduce the risk

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - pravastatin sodium (unii: 3m8608uq61) (pravastatin - unii:kxo2kt9n0g) - pravastatin sodium 20 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in hypercholesterolemic patients without clinically evident coronary heart disease (chd), pravastatin sodium tablets are indicated to: - reduce the risk of myocardial infarction (mi). - reduce the risk of undergoing myocardial revascularization procedures. - reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. in patients with clinically evident chd, pravastatin sodium is indicated to: - reduce the risk of total mortality by reducing coronary death. - reduce the risk of mi. - reduce the risk of undergoing myocardial revascularization procedures. - reduce the risk of strok

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

ncs healthcare of ky, llc dba vangard labs - pravastatin sodium (unii: 3m8608uq61) (pravastatin - unii:kxo2kt9n0g) - pravastatin sodium 20 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in hypercholesterolemic patients without clinically evident coronary heart disease (chd), pravastatin sodium tablets are indicated to: - reduce the risk of myocardial infarction (mi). - reduce the risk of undergoing myocardial revascularization procedures. - reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. in patients with clinically evident chd, pravastatin sodium tablets are indicated to: - reduce the risk of total mortality by reducing coronary death. - reduce the risk of mi. - reduce the risk of undergoing myocardial revascularization procedures. - reduce the risk

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - pravastatin sodium (unii: 3m8608uq61) (pravastatin - unii:kxo2kt9n0g) - pravastatin sodium 40 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in hypercholesterolemic patients without clinically evident coronary heart disease (chd), pravastatin sodium tablets usp are indicated to: - reduce the risk of myocardial infarction (mi). - reduce the risk of undergoing myocardial revascularization procedures. - reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. pravastatin sodium tablets usp are indicated: - as an adjunct to diet to reduce elevated total cholesterol (total-c), low-density lipoprotein cholesterol (ldl-c), apolipoprotein b (apob), and triglyceride (tg) levels and to increase high-density lipoprotein chol

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

proficient rx lp - pravastatin sodium (unii: 3m8608uq61) (pravastatin - unii:kxo2kt9n0g) - pravastatin sodium 20 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in hypercholesterolemic patients without clinically evident coronary heart disease (chd), pravastatin sodium tablets usp are indicated to: pravastatin sodium tablets usp are indicated: pravastatin sodium tablets usp have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (fredrickson types i and v). hypersensitivity to any component of this medication. active liver disease or unexplained, persistent elevations of serum transaminases [see warnings and precautions (5.2) ]. atherosclerosis is a chronic process and discontinuation of lipid-lowering drugs during pregnancy sho

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

sandoz inc - pravastatin sodium (unii: 3m8608uq61) (pravastatin - unii:kxo2kt9n0g) - pravastatin sodium 10 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in hypercholesterolemic patients without clinically evident coronary heart disease (chd), pravastatin sodium tablets are indicated to: pravastatin sodium tablets are indicated: pravastatin sodium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (fredrickson types i and v). hypersensitivity to any component of this medication. active liver disease or unexplained, persistent elevations of serum transaminases [see warnings and precautions (5.2) ] . atherosclerosis is a chronic process and discontinuation of lipid-lowering drugs during pregnancy shoul